6533b852fe1ef96bd12aabff
RESEARCH PRODUCT
Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies
Enrique Gómez-graciaÁNgel M. Alonso-gómezClary B. ClishMiguel ÁNgel Martínez-gonzálezJosé LapetraCourtney DennisCristina RazquinCristina RazquinDora RomagueraEmilio RosJun LiMarta Guasch-ferréMarta Guasch-ferréAlbert Salas-huetosAlbert Salas-huetosFrank B. HuFrank B. HuLiming LiangDolores CorellaDolores CorellaKerry A. PierceMontserrat FitóMiguel Ruiz-canelaMiguel Ruiz-canelaRamon EstruchLluis Serra-majemLluis Serra-majemEstefanía ToledoEstefanía ToledoJordi Salas-salvadóJordi Salas-salvadósubject
Malelcsh:Diseases of the circulatory (Cardiovascular) systemTime FactorsMediterranean dietEndocrinology Diabetes and MetabolismhumanosDiseaseType 2 diabetes030204 cardiovascular system & hematologyDiet Mediterraneanchemistry.chemical_compound0302 clinical medicineRisk Factorsestudios prospectivosevaluación de riesgosMetabolites030212 general & internal medicineProspective Studiesmediana edadOriginal InvestigationPipecolic acidRandomized Controlled Trials as TopicAged 80 and overancianodietaácidos pipecólicosensayos clínicos controlados aleatorizados como asuntoresultado del tratamientoIncidenceType 2 diabetesMiddle AgedCardiovascular disease3. Good healthPrimary PreventionTreatment OutcomeCardiovascular DiseasesPipecolic AcidsFemaleCardiology and Cardiovascular Medicineconducta de reducción del riesgoCohort studymedicine.medical_specialtyenfermedades cardiovascularesácido 2-aminoadípicoRisk Assessmentincidencia03 medical and health sciencesfactores de tiempoInternal medicineDiabetes mellitusmedicineDiabetes Mellitusfactores de riesgoHumansAngiologyAgedProportional hazards modelbusiness.industryLysinemedicine.diseaseDietlisinaDietary interventionchemistryDiabetes Mellitus Type 2lcsh:RC666-701business2-Aminoadipic AcidRisk Reduction BehaviorBiomarkersdescription
[Background]: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. [Methods]: Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. [Results]: In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. [Conclusions]: Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003.
year | journal | country | edition | language |
---|---|---|---|---|
2019-11-13 |